Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications.
We planned a phase I study of radiotherapy combined with weekly docetaxel for elderly patients or patients with complications to find out the optimal dose. Five consecutive weekly administrations of docetaxel were accompanied by radiotherapy for patients diagnosed with squamous cell carcinoma of the head and neck. The starting dose of docetaxel was 10 mg/m(2) with escalation at 2 mg/m(2) per step. Fifteen patients were enrolled in this trial. The maximal tolerated dose was 14 mg/m(2), so the recommended dose was determined as 12 mg/m(2). Hematological toxicity was sufficiently weak. Common dose-limiting toxicity was stomatitis within the radiation field. This protocol was thought to be practical for elderly patients or those with medical complications.